Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547740 | 1.00 | MAOA (0.42) | MAOAHSD17B10PRKDCALDH1A1HTR1A | |
| SCHEMBL19662132 | 1.00 | MAOA (0.42) | MAOAHSD17B10PRKDCALDH1A1HTR1A | |
| SCHEMBL19642323 | 0.99 | MAOA (0.43) | MAOAHSD17B10PRKDCALDH1A1HTR1A | |
| SCHEMBL19642388 | 0.89 | CYP1A1 (0.43) | MAOAPRKDCALDH1A1KIF11 | |
| SCHEMBL29547500 | 0.89 | HTR6 (0.40) | MAOAALDH1A1HTR1AHTR7HTR6 | |
| SCHEMBL19642697 | 0.89 | HTR6 (0.40) | MAOAALDH1A1HTR1AHTR7HTR6 | |
| SCHEMBL19642400 | 0.88 | HTR6 (0.49) | MAOAHTR1AHTR7HTR6XDH | |
| SCHEMBL19642402 | 0.86 | TTR (0.39) | MAOAALDH1A1TTR | |
| SCHEMBL19642379 | 0.84 | TTR (0.56) | MAOAHSD17B10ALDH1A1HTR1AHTR7 | |
| SCHEMBL19662320 | 0.83 | MAOA (0.39) | MAOAALDH1A1HTR1AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | claimed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | claimed |
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2020-04-07 | — | — | US | claimed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | claimed |
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3464278-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017202798-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017202798-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | XDH, XPOT, HAVCR2 | MAOA 851/4885HSD17B10 178/4885PRKDC 4879/4885 |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | XDH, HAVCR2, XPA | MAOA 821/4885HSD17B10 267/4885PRKDC 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.